远大医药自研创新FAP靶点核药美国临床获批

Core Viewpoint - The company, Far East Pharmaceutical, has received formal approval from the U.S. FDA to initiate Phase I/II clinical trials for its self-developed global innovative FAP-targeted radiopharmaceutical conjugate (RDC) GPN01530 for the diagnosis of solid tumors, marking its first FDA-approved self-researched RDC product [1] Group 1 - The FDA approval is a significant milestone for the company, indicating progress in its research and development efforts [1] - GPN01530 is specifically designed for the diagnosis of solid tumors, highlighting the company's focus on oncology [1] - This approval may enhance the company's position in the competitive pharmaceutical market, particularly in the field of radiopharmaceuticals [1]